Antimicrobial Agents and Chemotherapy · 2020 · 15 citations · 29 references
Life SciencesMicrobiologyPharmacologyAntimicrobial PharmacotherapyAntimicrobial ResistanceMedical MicrobiologyAntibacterial PharmacologyAntibacterial TherapyAntibiotic ResistanceAntimicrobial PharmacodynamicsAntimicrobial Susceptibility TestingMultidrug ResistanceAntibacterial PropertiesMultidrug-resistant OrganismsMultidrug-resistant PathogensPseudomonas Aeruginosa Infection TreatmentPseudomonas Aeruginosa ResistanceReductionsStandard Errors Of Measurement
Combination therapy may enhance imipenem/cilastatin/relebactam’s (I/R) activity against Pseudomonas aeruginosa and suppress resistance development. Human-simulated unbound plasma concentrations of I/R at 1.25 g every 6 h (h), colistin at 360 mg daily, and amikacin at 25 mg/kg daily were reproduced alone and in combination against six imipenem-nonsusceptible P. aeruginosa isolates in an in vitro pharmacodynamic model over 24 h.
29
Anna-Pelagia Magiorakos, Arjun Srinivasan, Roberta B. Carey et al. · Clinical Microbiology and Infection · 2011 · 14K citations
André C. Kalil, Mark L. Metersky, Michael Klompas et al. · Clinical Infectious Diseases · 2016 · 3.9K citations · Full text
J. Motsch, Cláudia Murta de Oliveira, V.P. Stus et al. · Clinical Infectious Diseases · 2019 · 404 citations · Full text